nodes	percent_of_prediction	percent_of_DWPC	metapath
Reboxetine—SLC6A4—attention deficit hyperactivity disorder	0.862	1	CbGaD
Reboxetine—SLC6A2—locus ceruleus—attention deficit hyperactivity disorder	0.0174	0.308	CbGeAlD
Reboxetine—SLC6A2—autonomic nervous system—attention deficit hyperactivity disorder	0.00925	0.164	CbGeAlD
Reboxetine—SLC6A4—Serotonin Transporter Activity—TPH2—attention deficit hyperactivity disorder	0.00506	0.0674	CbGpPWpGaD
Reboxetine—SLC6A4—Serotonin Transporter Activity—MAOA—attention deficit hyperactivity disorder	0.00305	0.0405	CbGpPWpGaD
Reboxetine—HTR2C—Serotonin receptors—HTR1B—attention deficit hyperactivity disorder	0.00282	0.0375	CbGpPWpGaD
Reboxetine—HTR2C—forebrain—attention deficit hyperactivity disorder	0.00258	0.0458	CbGeAlD
Reboxetine—SLC6A4—forebrain—attention deficit hyperactivity disorder	0.00245	0.0434	CbGeAlD
Reboxetine—SLC6A4—Monoamine Transport—TPH2—attention deficit hyperactivity disorder	0.00216	0.0287	CbGpPWpGaD
Reboxetine—SLC6A2—forebrain—attention deficit hyperactivity disorder	0.00216	0.0382	CbGeAlD
Reboxetine—SLC6A4—Monoamine Transport—HRH3—attention deficit hyperactivity disorder	0.00212	0.0282	CbGpPWpGaD
Reboxetine—HTR2C—Monoamine GPCRs—ADRA2C—attention deficit hyperactivity disorder	0.00211	0.0281	CbGpPWpGaD
Reboxetine—HTR2C—Monoamine GPCRs—DRD5—attention deficit hyperactivity disorder	0.00207	0.0275	CbGpPWpGaD
Reboxetine—SLC6A2—Na+/Cl- dependent neurotransmitter transporters—SLC6A3—attention deficit hyperactivity disorder	0.002	0.0267	CbGpPWpGaD
Reboxetine—Diphenylpyraline—SLC6A3—attention deficit hyperactivity disorder	0.00193	0.291	CrCbGaD
Reboxetine—SLC6A2—Monoamine Transport—TPH2—attention deficit hyperactivity disorder	0.00185	0.0247	CbGpPWpGaD
Reboxetine—SLC6A2—Monoamine Transport—HRH3—attention deficit hyperactivity disorder	0.00182	0.0243	CbGpPWpGaD
Reboxetine—HTR2C—Amine ligand-binding receptors—ADRA2C—attention deficit hyperactivity disorder	0.00178	0.0236	CbGpPWpGaD
Reboxetine—HTR2C—Amine ligand-binding receptors—DRD5—attention deficit hyperactivity disorder	0.00174	0.0231	CbGpPWpGaD
Reboxetine—HTR2C—midbrain—attention deficit hyperactivity disorder	0.00171	0.0302	CbGeAlD
Reboxetine—SLC6A4—midbrain—attention deficit hyperactivity disorder	0.00162	0.0287	CbGeAlD
Reboxetine—HTR2C—Serotonin receptors—HTR2A—attention deficit hyperactivity disorder	0.00161	0.0214	CbGpPWpGaD
Reboxetine—SLC6A4—Monoamine Transport—SLC6A3—attention deficit hyperactivity disorder	0.00154	0.0204	CbGpPWpGaD
Reboxetine—Benzatropine—SLC6A3—attention deficit hyperactivity disorder	0.00148	0.223	CrCbGaD
Reboxetine—SLC6A2—Monoamine Transport—SLC6A4—attention deficit hyperactivity disorder	0.00148	0.0197	CbGpPWpGaD
Reboxetine—HTR2C—nervous system—attention deficit hyperactivity disorder	0.0014	0.0248	CbGeAlD
Reboxetine—SLC6A2—Amine compound SLC transporters—SLC6A3—attention deficit hyperactivity disorder	0.00139	0.0185	CbGpPWpGaD
Reboxetine—HTR2C—central nervous system—attention deficit hyperactivity disorder	0.00135	0.0239	CbGeAlD
Reboxetine—SLC6A4—nervous system—attention deficit hyperactivity disorder	0.00133	0.0236	CbGeAlD
Reboxetine—SLC6A2—Monoamine Transport—SLC6A3—attention deficit hyperactivity disorder	0.00132	0.0176	CbGpPWpGaD
Reboxetine—SLC6A4—central nervous system—attention deficit hyperactivity disorder	0.00128	0.0227	CbGeAlD
Reboxetine—HTR2C—Monoamine GPCRs—HTR1B—attention deficit hyperactivity disorder	0.00125	0.0167	CbGpPWpGaD
Reboxetine—HTR2C—Amine ligand-binding receptors—HRH3—attention deficit hyperactivity disorder	0.00121	0.016	CbGpPWpGaD
Reboxetine—SLC6A4—Synaptic Vesicle Pathway—SNAP25—attention deficit hyperactivity disorder	0.00119	0.0158	CbGpPWpGaD
Reboxetine—CYP2D6—forebrain—attention deficit hyperactivity disorder	0.00118	0.0209	CbGeAlD
Reboxetine—SLC6A2—nervous system—attention deficit hyperactivity disorder	0.00117	0.0207	CbGeAlD
Reboxetine—HTR2C—Monoamine GPCRs—DRD1—attention deficit hyperactivity disorder	0.00117	0.0155	CbGpPWpGaD
Reboxetine—HTR2C—Monoamine GPCRs—DRD3—attention deficit hyperactivity disorder	0.00113	0.015	CbGpPWpGaD
Reboxetine—SLC6A2—central nervous system—attention deficit hyperactivity disorder	0.00113	0.02	CbGeAlD
Reboxetine—HTR2C—Monoamine GPCRs—ADRA2A—attention deficit hyperactivity disorder	0.00111	0.0148	CbGpPWpGaD
Reboxetine—HTR2C—Monoamine GPCRs—DRD4—attention deficit hyperactivity disorder	0.0011	0.0146	CbGpPWpGaD
Reboxetine—HTR2C—brain—attention deficit hyperactivity disorder	0.00107	0.019	CbGeAlD
Reboxetine—HTR2C—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—HTR2A—attention deficit hyperactivity disorder	0.00107	0.0142	CbGpPWpGaD
Reboxetine—HTR2C—Amine ligand-binding receptors—HTR1B—attention deficit hyperactivity disorder	0.00105	0.014	CbGpPWpGaD
Reboxetine—Atomoxetine—HTR1B—attention deficit hyperactivity disorder	0.00104	0.157	CrCbGaD
Reboxetine—HTR2C—Monoamine GPCRs—DRD2—attention deficit hyperactivity disorder	0.00102	0.0136	CbGpPWpGaD
Reboxetine—SLC6A4—brain—attention deficit hyperactivity disorder	0.00102	0.018	CbGeAlD
Reboxetine—HTR2C—Amine ligand-binding receptors—DRD1—attention deficit hyperactivity disorder	0.00098	0.013	CbGpPWpGaD
Reboxetine—HTR2C—Amine ligand-binding receptors—DRD3—attention deficit hyperactivity disorder	0.000949	0.0126	CbGpPWpGaD
Reboxetine—Atomoxetine—SLC6A3—attention deficit hyperactivity disorder	0.000944	0.142	CrCbGaD
Reboxetine—HTR2C—Amine ligand-binding receptors—ADRA2A—attention deficit hyperactivity disorder	0.000933	0.0124	CbGpPWpGaD
Reboxetine—HTR2C—Amine ligand-binding receptors—DRD4—attention deficit hyperactivity disorder	0.000921	0.0123	CbGpPWpGaD
Reboxetine—SLC6A2—brain—attention deficit hyperactivity disorder	0.000894	0.0158	CbGeAlD
Reboxetine—HTR2C—Amine ligand-binding receptors—DRD2—attention deficit hyperactivity disorder	0.000858	0.0114	CbGpPWpGaD
Reboxetine—ABCB1—forebrain—attention deficit hyperactivity disorder	0.000849	0.015	CbGeAlD
Reboxetine—ABCB1—cardiovascular system—attention deficit hyperactivity disorder	0.000718	0.0127	CbGeAlD
Reboxetine—HTR2C—Monoamine GPCRs—HTR2A—attention deficit hyperactivity disorder	0.000715	0.00951	CbGpPWpGaD
Reboxetine—SLC6A2—SLC-mediated transmembrane transport—SLC9A9—attention deficit hyperactivity disorder	0.00071	0.00945	CbGpPWpGaD
Reboxetine—Atomoxetine—SLC6A4—attention deficit hyperactivity disorder	0.000706	0.106	CrCbGaD
Reboxetine—CYP3A4—nervous system—attention deficit hyperactivity disorder	0.000651	0.0115	CbGeAlD
Reboxetine—CYP2D6—nervous system—attention deficit hyperactivity disorder	0.000641	0.0114	CbGeAlD
Reboxetine—CYP3A4—central nervous system—attention deficit hyperactivity disorder	0.000627	0.0111	CbGeAlD
Reboxetine—CYP2D6—central nervous system—attention deficit hyperactivity disorder	0.000617	0.0109	CbGeAlD
Reboxetine—SLC6A4—SIDS Susceptibility Pathways—TPH2—attention deficit hyperactivity disorder	0.000607	0.00808	CbGpPWpGaD
Reboxetine—CYP2D6—cerebellum—attention deficit hyperactivity disorder	0.000603	0.0107	CbGeAlD
Reboxetine—HTR2C—Amine ligand-binding receptors—HTR2A—attention deficit hyperactivity disorder	0.000601	0.00799	CbGpPWpGaD
Reboxetine—ABCB1—midbrain—attention deficit hyperactivity disorder	0.000561	0.00993	CbGeAlD
Reboxetine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—attention deficit hyperactivity disorder	0.000544	0.00724	CbGpPWpGaD
Reboxetine—Atomoxetine—HTR2A—attention deficit hyperactivity disorder	0.000542	0.0815	CrCbGaD
Reboxetine—SLC6A4—SIDS Susceptibility Pathways—CHRNA4—attention deficit hyperactivity disorder	0.000522	0.00694	CbGpPWpGaD
Reboxetine—CYP2D6—Melatonin metabolism and effects—MAOA—attention deficit hyperactivity disorder	0.000501	0.00666	CbGpPWpGaD
Reboxetine—SLC6A4—Circadian rythm related genes—TPH2—attention deficit hyperactivity disorder	0.000496	0.00659	CbGpPWpGaD
Reboxetine—CYP2D6—brain—attention deficit hyperactivity disorder	0.00049	0.00868	CbGeAlD
Reboxetine—SLC6A4—SIDS Susceptibility Pathways—SNAP25—attention deficit hyperactivity disorder	0.000485	0.00646	CbGpPWpGaD
Reboxetine—CYP3A4—Estrogen metabolism—COMT—attention deficit hyperactivity disorder	0.000483	0.00642	CbGpPWpGaD
Reboxetine—ABCB1—nervous system—attention deficit hyperactivity disorder	0.000461	0.00817	CbGeAlD
Reboxetine—SLC6A4—NRF2 pathway—SLC6A3—attention deficit hyperactivity disorder	0.000456	0.00607	CbGpPWpGaD
Reboxetine—ABCB1—central nervous system—attention deficit hyperactivity disorder	0.000444	0.00786	CbGeAlD
Reboxetine—SLC6A2—NRF2 pathway—SLC6A4—attention deficit hyperactivity disorder	0.00044	0.00585	CbGpPWpGaD
Reboxetine—ABCB1—cerebellum—attention deficit hyperactivity disorder	0.000434	0.00769	CbGeAlD
Reboxetine—HTR2C—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.000408	0.00542	CbGpPWpGaD
Reboxetine—HTR2C—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.000399	0.00531	CbGpPWpGaD
Reboxetine—HTR2C—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.000396	0.00527	CbGpPWpGaD
Reboxetine—SLC6A4—Circadian rythm related genes—DRD1—attention deficit hyperactivity disorder	0.000396	0.00527	CbGpPWpGaD
Reboxetine—SLC6A2—NRF2 pathway—SLC6A3—attention deficit hyperactivity disorder	0.000392	0.00522	CbGpPWpGaD
Reboxetine—SLC6A4—Circadian rythm related genes—DRD3—attention deficit hyperactivity disorder	0.000384	0.0051	CbGpPWpGaD
Reboxetine—SLC6A4—Circadian rythm related genes—DRD4—attention deficit hyperactivity disorder	0.000372	0.00496	CbGpPWpGaD
Reboxetine—SLC6A4—SIDS Susceptibility Pathways—MAOA—attention deficit hyperactivity disorder	0.000365	0.00486	CbGpPWpGaD
Reboxetine—SLC6A2—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.000361	0.0048	CbGpPWpGaD
Reboxetine—SLC6A4—SIDS Susceptibility Pathways—BDNF—attention deficit hyperactivity disorder	0.000352	0.00469	CbGpPWpGaD
Reboxetine—ABCB1—brain—attention deficit hyperactivity disorder	0.000352	0.00624	CbGeAlD
Reboxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.000349	0.00465	CbGpPWpGaD
Reboxetine—SLC6A4—Circadian rythm related genes—DRD2—attention deficit hyperactivity disorder	0.000347	0.00462	CbGpPWpGaD
Reboxetine—SLC6A2—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.000344	0.00458	CbGpPWpGaD
Reboxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.000342	0.00455	CbGpPWpGaD
Reboxetine—SLC6A4—SIDS Susceptibility Pathways—HTR2A—attention deficit hyperactivity disorder	0.000298	0.00396	CbGpPWpGaD
Reboxetine—HTR2C—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.000277	0.00368	CbGpPWpGaD
Reboxetine—HTR2C—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.000266	0.00354	CbGpPWpGaD
Reboxetine—HTR2C—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.00026	0.00347	CbGpPWpGaD
Reboxetine—SLC6A2—SLC-mediated transmembrane transport—SLC6A3—attention deficit hyperactivity disorder	0.000247	0.00329	CbGpPWpGaD
Reboxetine—HTR2C—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.000242	0.00322	CbGpPWpGaD
Reboxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.000237	0.00315	CbGpPWpGaD
Reboxetine—CYP2D6—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.000227	0.00302	CbGpPWpGaD
Reboxetine—HTR2C—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.000225	0.00299	CbGpPWpGaD
Reboxetine—HTR2C—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.000224	0.00298	CbGpPWpGaD
Reboxetine—HTR2C—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.000218	0.0029	CbGpPWpGaD
Reboxetine—HTR2C—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.000214	0.00285	CbGpPWpGaD
Reboxetine—HTR2C—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.000211	0.00281	CbGpPWpGaD
Reboxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.000207	0.00276	CbGpPWpGaD
Reboxetine—HTR2C—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.000203	0.00271	CbGpPWpGaD
Reboxetine—HTR2C—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.000197	0.00262	CbGpPWpGaD
Reboxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.000193	0.00256	CbGpPWpGaD
Reboxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.000187	0.00248	CbGpPWpGaD
Reboxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.000183	0.00244	CbGpPWpGaD
Reboxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.000181	0.00241	CbGpPWpGaD
Reboxetine—HTR2C—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.000181	0.0024	CbGpPWpGaD
Reboxetine—HTR2C—G alpha (q) signalling events—HTR2A—attention deficit hyperactivity disorder	0.000178	0.00237	CbGpPWpGaD
Reboxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.000169	0.00225	CbGpPWpGaD
Reboxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	0.00016	0.00212	CbGpPWpGaD
Reboxetine—ABCB1—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.000159	0.00211	CbGpPWpGaD
Reboxetine—HTR2C—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.000158	0.0021	CbGpPWpGaD
Reboxetine—SLC6A4—SIDS Susceptibility Pathways—EP300—attention deficit hyperactivity disorder	0.000158	0.0021	CbGpPWpGaD
Reboxetine—ABCB1—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.000152	0.00202	CbGpPWpGaD
Reboxetine—HTR2C—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.00015	0.002	CbGpPWpGaD
Reboxetine—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.000148	0.00197	CbGpPWpGaD
Reboxetine—HTR2C—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.000147	0.00196	CbGpPWpGaD
Reboxetine—HTR2C—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.000147	0.00195	CbGpPWpGaD
Reboxetine—HTR2C—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.000142	0.00189	CbGpPWpGaD
Reboxetine—HTR2C—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.00014	0.00186	CbGpPWpGaD
Reboxetine—HTR2C—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.000138	0.00184	CbGpPWpGaD
Reboxetine—HTR2C—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.000138	0.00184	CbGpPWpGaD
Reboxetine—HTR2C—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.000136	0.00182	CbGpPWpGaD
Reboxetine—HTR2C—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.000134	0.00178	CbGpPWpGaD
Reboxetine—SLC6A4—Circadian rythm related genes—EP300—attention deficit hyperactivity disorder	0.000129	0.00171	CbGpPWpGaD
Reboxetine—HTR2C—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.000129	0.00171	CbGpPWpGaD
Reboxetine—SLC6A2—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.000126	0.00167	CbGpPWpGaD
Reboxetine—CYP2D6—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000121	0.00161	CbGpPWpGaD
Reboxetine—CYP2D6—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000121	0.0016	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00012	0.0016	CbGpPWpGaD
Reboxetine—CYP2D6—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00012	0.00159	CbGpPWpGaD
Reboxetine—ABCB1—HIF-1-alpha transcription factor network—EP300—attention deficit hyperactivity disorder	0.000119	0.00158	CbGpPWpGaD
Reboxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.000118	0.00157	CbGpPWpGaD
Reboxetine—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—attention deficit hyperactivity disorder	0.000113	0.00151	CbGpPWpGaD
Reboxetine—HTR2C—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.000102	0.00136	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	9.38e-05	0.00125	CbGpPWpGaD
Reboxetine—HTR2C—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	9.27e-05	0.00123	CbGpPWpGaD
Reboxetine—HTR2C—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	9e-05	0.0012	CbGpPWpGaD
Reboxetine—HTR2C—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	8.92e-05	0.00119	CbGpPWpGaD
Reboxetine—HTR2C—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	8.29e-05	0.0011	CbGpPWpGaD
Reboxetine—HTR2C—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	8.1e-05	0.00108	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	8.06e-05	0.00107	CbGpPWpGaD
Reboxetine—HTR2C—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	8.03e-05	0.00107	CbGpPWpGaD
Reboxetine—CYP3A4—Biological oxidations—COMT—attention deficit hyperactivity disorder	7.93e-05	0.00106	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	7.9e-05	0.00105	CbGpPWpGaD
Reboxetine—HTR2C—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	7.89e-05	0.00105	CbGpPWpGaD
Reboxetine—CYP3A4—Biological oxidations—MAOA—attention deficit hyperactivity disorder	7.88e-05	0.00105	CbGpPWpGaD
Reboxetine—CYP3A4—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	7.83e-05	0.00104	CbGpPWpGaD
Reboxetine—HTR2C—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	7.8e-05	0.00104	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	7.74e-05	0.00103	CbGpPWpGaD
Reboxetine—HTR2C—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	7.53e-05	0.001	CbGpPWpGaD
Reboxetine—HTR2C—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	7.29e-05	0.00097	CbGpPWpGaD
Reboxetine—HTR2C—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	7.26e-05	0.000966	CbGpPWpGaD
Reboxetine—HTR2C—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	7.17e-05	0.000954	CbGpPWpGaD
Reboxetine—HTR2C—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	7.08e-05	0.000942	CbGpPWpGaD
Reboxetine—HTR2C—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	6.59e-05	0.000877	CbGpPWpGaD
Reboxetine—ABCB1—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	5.53e-05	0.000736	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	5.47e-05	0.000728	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	5.27e-05	0.000701	CbGpPWpGaD
Reboxetine—HTR2C—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	5.09e-05	0.000677	CbGpPWpGaD
Reboxetine—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	5.08e-05	0.000676	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—ADRA2C—attention deficit hyperactivity disorder	4.96e-05	0.00066	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	4.78e-05	0.000637	CbGpPWpGaD
Reboxetine—HTR2C—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	4.62e-05	0.000615	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	4.45e-05	0.000592	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	4.31e-05	0.000573	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	4.23e-05	0.000563	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	4.18e-05	0.000556	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	3.9e-05	0.000518	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—TPH2—attention deficit hyperactivity disorder	3.64e-05	0.000484	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—CACNB2—attention deficit hyperactivity disorder	3.64e-05	0.000484	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—DPYD—attention deficit hyperactivity disorder	3.58e-05	0.000476	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—CACNB2—attention deficit hyperactivity disorder	3.43e-05	0.000456	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—TPH2—attention deficit hyperactivity disorder	3.43e-05	0.000456	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—DPYD—attention deficit hyperactivity disorder	3.37e-05	0.000448	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	3.32e-05	0.000442	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—ADRA2C—attention deficit hyperactivity disorder	3.24e-05	0.000432	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—CACNA1C—attention deficit hyperactivity disorder	3.13e-05	0.000417	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—SNAP25—attention deficit hyperactivity disorder	2.91e-05	0.000387	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	2.77e-05	0.000368	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—SNAP25—attention deficit hyperactivity disorder	2.74e-05	0.000364	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.73e-05	0.000363	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—ADRA2A—attention deficit hyperactivity disorder	2.61e-05	0.000347	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—TPH2—attention deficit hyperactivity disorder	2.24e-05	0.000298	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—CACNB2—attention deficit hyperactivity disorder	2.24e-05	0.000298	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—DPYD—attention deficit hyperactivity disorder	2.2e-05	0.000293	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—COMT—attention deficit hyperactivity disorder	2.2e-05	0.000293	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—MAOA—attention deficit hyperactivity disorder	2.19e-05	0.000291	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—COMT—attention deficit hyperactivity disorder	2.08e-05	0.000276	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—MAOA—attention deficit hyperactivity disorder	2.06e-05	0.000274	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—CACNA1C—attention deficit hyperactivity disorder	2.05e-05	0.000273	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.79e-05	0.000238	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.7e-05	0.000227	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.45e-05	0.000192	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—COMT—attention deficit hyperactivity disorder	1.36e-05	0.000181	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—MAOA—attention deficit hyperactivity disorder	1.35e-05	0.000179	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—EP300—attention deficit hyperactivity disorder	9.44e-06	0.000126	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—EP300—attention deficit hyperactivity disorder	8.9e-06	0.000118	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—EP300—attention deficit hyperactivity disorder	5.82e-06	7.74e-05	CbGpPWpGaD
